 "Biocon surges 11% ahead of USFDA meet for new drug filing")
Shares of Biocon surged as much as 11% to Rs 360 in intraday ahead of the USFDA meet to discuss its breast cancer drug filing.
The US drug regulator’s Advisory Committee (Adcom) will be meeting on July 13 to discuss trastuzumab filing done by Mylan, Biocon’s partner. Trastuzumab is used to treat metastatic (spread) breast cancer.
The scrip plunged over 9% during Monday’s trade on the BSE as the French inspecting authority (ANSM) found lapses at Biocon's Bengaluru plant.
The stock fell around one third of a percent in the past one month, while its three-day gain stood at over 2%.
At 12:19 pm, Biocon was quoting at Rs 355, up 10% on the BSE. It touched an intraday high of Rs 360 and an intraday low of Rs 340.
So far 5.2 million shares traded on the counter. The current market cap of the company is Rs 19,386 crore.
The US drug regulator’s Advisory Committee (Adcom) will be meeting on July 13 to discuss trastuzumab filing done by Mylan, Biocon’s partner. Trastuzumab is used to treat metastatic (spread) breast cancer.
The scrip plunged over 9% during Monday’s trade on the BSE as the French inspecting authority (ANSM) found lapses at Biocon's Bengaluru plant.
Also Read
At 12:19 pm, Biocon was quoting at Rs 355, up 10% on the BSE. It touched an intraday high of Rs 360 and an intraday low of Rs 340.
So far 5.2 million shares traded on the counter. The current market cap of the company is Rs 19,386 crore.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%